Colossal Biosciences Seeks New Funding at $20B-$30B Valuation Amid Revenue Growth

Global — Ekhbary News Agency

The de-extinction startup Colossal Biosciences is reportedly in discussions to secure fresh capital, potentially pushing its valuation to an impressive $20 billion to $30 billion. This comes roughly 16 months after the company, known for its ambitious projects like "resurrecting" the dire wolf, was valued at $10.2 billion. The reported fundraising effort, highlighted by Axios, underscores a significant surge in investor confidence in deep-tech sectors, particularly those at the intersection of biology and advanced engineering.

Colossal's Evolving Revenue Streams

While specifics regarding the lead investor or the exact capital sought remain unclear, the five-year-old company has, for what it's worth, begun generating revenue over the past year. CEO Ben Lamm previously outlined three primary income avenues for Colossal. These include offering its specialized conservation technology to entities like the U.S. government and the UAE, which recently committed $60 million to the firm. Furthermore, Colossal has successfully spun off three distinct startups, each contributing to its broader ecosystem.

Strategic Spin-offs and Future Prospects

Among Colossal's spin-offs are Breaking, a company focused on plastic degradation; Form Bio, a computational biology platform that recently secured $30 million in funding; and Astromech, an AI-driven predictive modeling firm in life sciences, which alone commanded a $2 billion valuation in March. Lamm also revealed plans to commercialize the company's artificial animal womb technology, with potential applications extending to human fertility treatments, expected to be ready next year. Should Colossal succeed in reintroducing extinct species like the woolly mammoth and dodo bird, future revenue could emerge from the sale of biodiversity credits, a market mechanism akin to carbon credits, as Lamm suggested.